GCC Nursing Guide — Polycystic Ovary Syndrome (PCOS)

What is PCOS?

Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in reproductive-age women, affecting 8–13% globally. It is characterised by a triad of hormonal, metabolic, and reproductive abnormalities. Diagnosis requires 2 of 3 Rotterdam criteria.

8–13%Global Prevalence

up to 20%GCC Prevalence

×5–7T2DM Risk Increase

50–80%Have Insulin Resistance

Rotterdam Criteria (2003) — Diagnosis requires 2 of 3:

Oligo/anovulation (irregular or absent periods — cycles >35 days, or fewer than 8/year)
Clinical or biochemical hyperandrogenism (acne, hirsutism, alopecia; elevated testosterone or DHEAS)
Polycystic ovaries on USS: ≥12 follicles measuring 2–9mm per ovary, OR ovarian volume >10 mL per ovary

Note: Other causes (CAH, Cushing's syndrome, hyperprolactinaemia, thyroid dysfunction) must be excluded first.

Hormonal Abnormalities

Hormone	Change	Clinical Effect
LH	Elevated; pulsatile frequency increased	Drives androgen production by theca cells
FSH	Normal or low	Insufficient for follicle maturation
LH:FSH ratio	>2 (often >3)	Frequently quoted — NOT a diagnostic criterion
Testosterone (total/free)	Elevated	Hirsutism, acne, alopecia
DHEAS (adrenal androgen)	Elevated (in ~50%)	Adrenal contribution to hyperandrogenism
SHBG	Decreased	More free (active) testosterone circulating
Insulin	Elevated (hyperinsulinaemia)	Stimulates ovarian androgen production; increases LH sensitivity
AMH	Elevated ×3–4	Reflects large antral follicle pool; used in IVF monitoring

Clinical Phenotypes

Four phenotypes exist based on combination of Rotterdam criteria features:

Phenotype	Features	Metabolic Risk
A (Classic)	Oligo/anov + HA + PCO	Highest
B	Oligo/anov + HA (no PCO on USS)	High
C (Ovulatory)	HA + PCO (regular cycles)	Moderate
D (Mild)	Oligo/anov + PCO (no HA)	Lower

HA = Hyperandrogenism; PCO = Polycystic ovaries on USS; Oligo/anov = Irregular/absent ovulation

Clinical Assessment

History

Menstrual history: cycle length, regularity, duration of bleeding, dysmenorrhoea
Fertility history: trying to conceive, previous pregnancies, miscarriages
Hirsutism: sites, duration, progression; Ferriman-Gallwey score
Acne: severity, duration, previous treatments
Hair loss: pattern (male-pattern alopecia)
Weight: recent changes; BMI; waist circumference
Family history: T2DM, PCOS, cardiovascular disease
Mood: anxiety, depression symptoms — screen routinely
Medications: current, including herbal remedies

Physical Examination

BMI, waist circumference (central obesity)
Blood pressure (cardiovascular risk)
Ferriman-Gallwey score: scores 9 body areas 0–4; score >8 = clinical hirsutism
Acne severity (comedonal, inflammatory, nodular)
Hair loss pattern assessment
Acanthosis nigricans: velvety darkening of skin folds (neck, axillae) = insulin resistance
Thyroid palpation
Signs of Cushing's (exclude if clinically suspected)

Investigations

Investigation	Finding in PCOS	Purpose
Total testosterone (day 2–5 of cycle)	Elevated (>2.5 nmol/L)	Confirm biochemical hyperandrogenism
SHBG	Decreased	Free androgen index calculation
DHEAS	Elevated (adrenal source)	Distinguish adrenal vs ovarian androgen excess
LH & FSH (Day 2–3)	LH elevated; LH:FSH >2 (not diagnostic)	Hormonal pattern assessment
AMH	Elevated ×3–4 normal	Antral follicle count surrogate; guides IVF
Fasting glucose + insulin (HOMA-IR)	Elevated insulin; impaired glucose	Insulin resistance quantification
OGTT (75g) + HbA1c	May show IGT or T2DM	Screen ALL PCOS patients for glucose dysregulation
Fasting lipid profile	Elevated TG; low HDL; elevated LDL	Metabolic syndrome assessment
TFTs (TSH)	Normal (to exclude thyroid disease)	Differential diagnosis exclusion
Prolactin	Normal or mildly elevated	Exclude hyperprolactinaemia (causes oligomenorrhoea)
17-OH Progesterone (morning, follicular)	Normal (<6 nmol/L)	Exclude late-onset congenital adrenal hyperplasia (CAH)
Pelvic USS (transvaginal preferred)	≥12 follicles 2–9mm OR volume >10 mL per ovary	Morphological criteria for PCOS diagnosis

Lifestyle Intervention — First-Line for All

Weight loss of 5–10% body weight in overweight/obese women with PCOS can restore ovulation, improve insulin sensitivity, reduce androgen levels, and improve metabolic profile — even without medication.

Calorie-restricted diet: Mediterranean diet or low-glycaemic-index approach preferred
Physical activity: minimum 150 min/week moderate-intensity aerobic exercise
Resistance training improves insulin sensitivity independently of weight loss
Weight loss of 5% → significant improvement in menstrual regularity and ovulation
Behavioural support and CBT for emotional eating, body image concerns

Pharmacological Management — Overview

Indication	Drug	Mechanism	Notes
Menstrual regulation + hyperandrogenism	Combined oral contraceptive pill (OCP)	Suppresses LH → reduces ovarian androgen; increases SHBG → reduces free testosterone	First-line for non-fertility women; choose low-androgen progestogen (e.g. drospirenone, cyproterone acetate)
Insulin resistance / metabolic	Metformin	Improves insulin sensitivity; reduces androgen production; modest effect on ovulation	Especially if impaired glucose tolerance (IGT) or T2DM; useful in obese PCOS; start low-dose and titrate
Ovulation induction	Letrozole (preferred) or Clomifene citrate	Letrozole: aromatase inhibitor → increased FSH; Clomifene: anti-oestrogen → increased GnRH/FSH	Letrozole preferred in overweight women (fewer side effects, better ovulation rates); monitor follicle development
Hirsutism	Spironolactone, Cyproterone acetate, Flutamide	Anti-androgens — block androgen receptors or reduce production	Contraception required (teratogenic in males); 6 months minimum for hair effect; eflornithine cream for facial hirsutism
Acne	OCP + topical retinoids, oral antibiotics	Hormonal + local anti-inflammatory	Dermatology referral for severe acne; avoid tetracyclines in pregnancy

Fertility Management Pathway

PCOS is the most common cause of anovulatory infertility. Management follows a stepwise approach from least to most invasive.

Step	Intervention	Notes
1st line	Lifestyle modification, weight loss	5–10% weight loss can restore spontaneous ovulation
2nd line	Oral ovulation induction: Letrozole (preferred) or Clomifene 50–150 mg days 2–6	Monitor with transvaginal USS; max 6 cycles; letrozole preferred in overweight and for better singleton rates
3rd line	Add metformin to clomifene (clomifene-resistant PCOS)	Metformin 1.5–2g/day improves clomifene response
4th line	Gonadotropin injections (FSH) — low-dose step-up protocol	Specialist-only; risk of OHSS (ovarian hyperstimulation syndrome); close ultrasound monitoring
5th line	Laparoscopic Ovarian Drilling (LOD)	Electrosurgical punctures in ovary reduce androgen-producing stroma; similar success to gonadotropins
6th line	IVF (In vitro fertilisation)	Last resort; high OHSS risk in PCOS; antagonist protocol preferred; elective frozen embryo transfer reduces OHSS

Psychological Support

PCOS has significant psychological impact: screen all patients for depression, anxiety, and eating disorders — rates are 2–3× higher than general population.

Anxiety: body image concerns, hirsutism, acne, weight — validated screening tools (GAD-7, PHQ-9)
Depression: chronic condition, fertility concerns, cultural pressure in GCC regarding fertility
Eating disorders: binge eating disorder common in PCOS (disordered eating patterns + insulin resistance)
Refer to psychologist/counsellor; CBT has evidence for body image and mood
Peer support groups and patient education are beneficial
Sexual dysfunction: low libido related to androgen imbalance and body image — address openly

Long-Term Complications of PCOS

Complication	Mechanism	Risk / Management
Type 2 Diabetes	Insulin resistance + beta-cell dysfunction over time	×5–7 increased risk vs non-PCOS; screen annually with OGTT; lifestyle + metformin if IGT
Metabolic Syndrome	Central obesity + insulin resistance + dyslipidaemia + hypertension	~30–40% of PCOS women; annual BP, lipid, and glucose monitoring
Cardiovascular Disease	Atherosclerosis driven by metabolic syndrome, inflammation, and androgen excess	Increased CVD risk — target modifiable risk factors: BP, lipids, smoking, weight
Endometrial Hyperplasia / Cancer	Irregular cycles → chronic anovulation → unopposed oestrogen → endometrial proliferation	Withdraw progesterone every 3–4 months if no natural periods; ultrasound for endometrial thickness; biopsy if >10 mm or abnormal bleeding
Gestational Diabetes	Pre-existing insulin resistance worsens in pregnancy	Screen at booking and 24–28 weeks; OGTT; lifestyle + insulin if required
Pre-eclampsia	Insulin resistance + obesity + metabolic syndrome in pregnancy	Aspirin prophylaxis in high-risk PCOS pregnancies; close antenatal surveillance
Obstructive Sleep Apnoea	Obesity + androgen excess → upper airway muscle dysfunction	Screen if BMI >30; refer for sleep study; CPAP if confirmed
Psychological comorbidities	Chronic condition; body image; fertility anxiety; cultural pressure	Annual mental health screening; CBT; peer support

PCOS in the GCC Region

PCOS prevalence in GCC countries is among the highest globally, with studies reporting rates up to 18–20% in some populations. Contributing factors include high rates of obesity, vitamin D deficiency, sedentary lifestyles, and possible genetic predisposition in Middle Eastern populations.

~18–20%PCOS Prevalence GCC

>80%Vitamin D Deficient GCC Women

HighCultural Fertility Pressure

Vitamin D Deficiency & PCOS in GCC ▼

Vitamin D deficiency is almost universal in GCC women (prevalence >80%) due to limited sun exposure (cultural dress, indoor lifestyles, UV avoidance). This is clinically significant in PCOS:

Vitamin D deficiency worsens insulin resistance — exacerbating PCOS metabolic features
Low vitamin D associated with higher testosterone levels in PCOS
Supplementation studies show modest improvement in insulin sensitivity and menstrual regularity
Routine screening of 25-OH Vitamin D in GCC PCOS patients is recommended
Supplement to achieve levels >75 nmol/L; typical dose 2000–4000 IU/day in deficiency
SCFHS and DHA exam tip: vitamin D-insulin resistance link in GCC PCOS is a frequently tested concept

Cultural Pressures — Fertility & GCC Nursing Care ▼

In GCC culture, fertility is closely tied to social identity and marital relationships; infertility carries significant social stigma
Women with PCOS may delay seeking medical care due to embarrassment about hirsutism, acne, or weight
Nurses should create a culturally safe, non-judgmental environment; offer same-gender consultations
Family involvement: husbands and mothers-in-law may influence fertility treatment decisions
IVF is widely available and culturally accepted in GCC (Islamic rulings generally permit IVF between married couples)
Egg donation is not permitted in most GCC countries under Islamic law — a key distinction
Psychological support integrated into gynaecological care pathways in UAE, Saudi Arabia (DHA/MOH)

Ramadan Fasting with PCOS Medications ▼

Metformin during Ramadan: take at Iftar and Suhoor; generally safe; GI side effects may improve with intermittent fasting schedule
OCP during Ramadan: take at the same time daily (Iftar recommended); pill-free week may be deferred to avoid menstruation during Ramadan
Clomifene/Letrozole: ovulation induction cycles can be planned to avoid Ramadan — consult gynaecologist in advance
Gonadotropin injections: not appropriate to start new cycles during Ramadan — plan around it
Fasting may temporarily improve insulin sensitivity — some studies show beneficial effects in PCOS
However: extreme calorie restriction + dehydration may cause cycle disruption; balanced approach recommended
Nurse role: pre-Ramadan counselling for all PCOS patients on medication adjustments

High-Yield Exam Facts for DHA / DOH / HAAD / SCFHS / QCHP

Rotterdam criteria: 2 of 3 — oligo/anovulation; clinical/biochemical HA; PCO on USS
PCOS is the most common endocrine disorder in reproductive-age women (8–13%)
LH:FSH ratio >2 is frequently quoted but NOT a diagnostic criterion
Ferriman-Gallwey score >8 = clinical hirsutism
Acanthosis nigricans = insulin resistance marker
ALL PCOS patients should be screened with OGTT for glucose dysregulation
5–10% weight loss can restore ovulation in overweight PCOS women
OCP: first-line for menstrual regulation + hyperandrogenism in non-fertility women
Letrozole preferred over clomifene for ovulation induction in overweight women
Metformin: used in PCOS for insulin sensitisation, especially if IGT/T2DM
Endometrial cancer risk: irregular periods → unopposed oestrogen → hyperplasia
Progesterone withdrawal every 3–4 months needed if no natural cycles
T2DM risk in PCOS: ×5–7 increased; annual OGTT recommended
GCC: vitamin D deficiency worsens insulin resistance in PCOS — screen and supplement

Practice MCQs

1. A 24-year-old woman presents with oligomenorrhoea, acne, and hirsutism. Pelvic USS shows normal-sized ovaries with 10 follicles per ovary. What is the correct statement regarding PCOS diagnosis?

A. She cannot have PCOS as she has fewer than 12 follicles per ovary

B. She meets Rotterdam criteria with 2 features (oligo/anovulation + clinical hyperandrogenism)

C. An LH:FSH ratio >2 is required to confirm PCOS diagnosis

D. She requires all 3 Rotterdam criteria to be met for diagnosis

Correct: B. Rotterdam criteria require only 2 of 3 features. This patient has oligomenorrhoea (ovulatory dysfunction) and clinical hyperandrogenism (hirsutism + acne). Polycystic ovaries on USS are not required if the other two criteria are met. LH:FSH ratio is NOT a diagnostic criterion.

2. A 28-year-old woman with PCOS and a BMI of 32 kg/m² is trying to conceive. She has had no response to two cycles of clomifene 50 mg. What is the most appropriate next management step?

A. Proceed directly to IVF

B. Increase clomifene to maximum dose 200 mg

C. Switch to letrozole or add metformin; consider increasing clomifene dose to 100–150 mg with monitoring

D. Laparoscopic ovarian drilling is the second-line treatment

Correct: C. For clomifene-resistant or overweight PCOS, letrozole is preferred (better success rates, lower multiple pregnancy risk). Adding metformin to clomifene also improves response in insulin-resistant PCOS. IVF and laparoscopic drilling are later-line options.

3. A woman with PCOS has had no menstrual period for 5 months. What is the primary long-term risk from chronic anovulation if untreated?

A. Ovarian cancer due to repeated follicle stimulation

B. Premature ovarian insufficiency

C. Endometrial hyperplasia progressing to endometrial cancer due to unopposed oestrogen

D. Cervical cancer due to chronic inflammation

Correct: C. Chronic anovulation means no corpus luteum → no progesterone production → unopposed oestrogen stimulates the endometrium continuously → endometrial hyperplasia → increased risk of endometrial cancer. Progesterone withdrawal (cyclical progestogen or OCP) protects the endometrium and must be prescribed if periods are fewer than 3–4 per year.

4. A nurse is counselling a 26-year-old GCC woman newly diagnosed with PCOS and a BMI of 29 kg/m². She is not currently trying to conceive. What is the first-line recommendation?

A. Start clomifene citrate to regulate cycles

B. Lifestyle modification (diet and exercise) as first-line; combined OCP for menstrual regulation and hyperandrogenism

C. Metformin as first-line pharmacological treatment for all PCOS women

D. Refer immediately to infertility specialist

Correct: B. Lifestyle modification (5–10% weight loss) is first-line for ALL PCOS women. For non-fertility management of menstrual irregularity and hyperandrogenism, the combined oral contraceptive pill (OCP) is the standard pharmacological first-line treatment. Metformin is indicated primarily for metabolic/glucose management. Clomifene is for fertility only.